Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

NCT07672769 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Higher Risk Myelodysplastic Syndromes

Interventions

DRUG: bexmarilimab (1mg/kg)
DRUG: azacitidine
DRUG: Placebo
DRUG: bexmarilimab (3mg/kg)

Sponsor

Faron Pharmaceuticals Ltd